In which patient population are you testing GAD7/ZnT8/Islet Cell Antibodies/C-peptide levels for a new diagnosis of diabetes?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

How do you decide when data patients bring to you for review/interpretation from a direct-to-consumer CGM is clinically useful and has it changed any of your management decisions in metabolically at-risk patients?

For patients with cardiovascular disease, kidney disease, and diabetes who also have cost constraints for prescription drugs, what factors most significantly impact your decision to start an SGLT2i OR GLP-1 agonists?

How do you approach the risk/benefit discussion for IV iron in a patient with concomitant severe iron deficiency and elevated hematocrit due to supra-physiologic testosterone supplementation?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.